Molecular Profile
What Is Cagrilintide?
TypeLong-acting acylated amylin analog
Amino acids37 (modified amylin sequence)
Molecular weight4,409 g/mol
CAS Number1415456-99-3
Molecular formulaC₁₉₄H₃₁₂N₅₄O₅₉S₂
ModificationC18 fatty diacid acylation
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Metabolic Research Peptide
Cagrilintide
NN9838CAS: 1415456-99-3ZP8396
A 37-amino acid long-acting acylated amylin analog that activates amylin and calcitonin receptors to modulate appetite signaling in homeostatic and hedonic brain regions, studied in clinical trials for weight management. Premium Research Peptide.
Dosage
Quantity
1
$69.99
Dosage
Quantity
1
$69.99
Mon, May 4 - Fri, May 8
Overnight shipping available
We accept
Cagrilintide$69.99
Free shippingon orders over $150
Damageprotection
Secure checkout256-bit SSL
Compound Information
Technical specifications
PubChem — CID 171397054
Storage Requirements
Stability Information
Store frozen or refrigeratedAvoid repeated freeze-thawProtect from light
Lyophilized (powder)
Store at -20°C long-term
Reconstituted
2-8°C•use within days
Light protection
Protect from light
Sources & References
Peer-reviewed research
New England Journal of Medicine
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025•DOI: 10.1056/NEJMoa2502081
Garvey WT, Blüher M, Osorto Contreras CK et al.
View Source
The LancetOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2021•PMID: 34798060
Lau DCW et al.
View Source
The LancetSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
2021•PMID: 33894838
Enebo LB et al.
View Source
Nature CommunicationsStructural and dynamic features of cagrilintide binding to calcitonin-family receptors
2025
View Source
Journal of Medicinal ChemistryDevelopment of Cagrilintide, a Long-Acting Amylin Analogue
2021
View Source
Cardiology in ReviewCagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
2024•DOI: 10.1097/CRD.0000000000000513•PMID: 36883831
D'Ascanio AM, Mullally JA, Frishman WH
View Source
PMCCagrilintide lowers bodyweight through brain amylin receptors 1 and 3
2025
View Source
PubChemCagrilintide — CID 171397054
View Source
Novo Nordisk (Press Release)CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
2026
View Source
ClinicalTrials.govREDEFINE 1 — A Research Study to See How Well CagriSema Works in People Living With Overweight or Obesity
View Source
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
